A5003748485- Colorectal Cancer Surgical Treatments
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Lymphoma Diagnosis and Treatment
- Urological Disorders and Treatments
- CAR-T cell therapy research
- Tendon Structure and Treatment
- Urinary Bladder and Prostate Research
- Body Contouring and Surgery
- Pediatric Urology and Nephrology Studies
- Bladder and Urothelial Cancer Treatments
- COVID-19 Clinical Research Studies
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Clinical practice guidelines implementation
- Orthopedic Surgery and Rehabilitation
- Ureteral procedures and complications
- Vascular Tumors and Angiosarcomas
- Lung Cancer Diagnosis and Treatment
- Esophageal and GI Pathology
- Pancreatic and Hepatic Oncology Research
- COVID-19 and healthcare impacts
- Colorectal Cancer Treatments and Studies
Loyola University Chicago
2023-2024
Loyola University Medical Center
2023
Sarcoma Oncology Center
2021-2022
11567 Background: Combination trabectidin (T) and nivolumab (N) has been shown to be a safe effective therapy in soft tissue sarcoma (STS). Intratumoral injection of talimogene laherparepvec (TVEC) local oncolytic effect, increases immune response via enhanced recruitment antigen presenting cells, thereby cytotoxic response. This study aims determine if the addition TVEC combination trabectedin is advanced sarcoma. Methods: Eligible patients include ≥ 18 years age with locally unresectable...
11573 Background: Understanding the bifunctional role that immune system plays in tumor eradication vs growth promotion is critical design and timing of tumoricidal immunologic therapies for sarcomas. Hypothesis: Immune checkpoint inhibitors promote sustained T cell activation would be most effective when given as first line therapy, together with a agent. Methods: Eligible patients this Phase 2 study are males or females ≥ 18 years age locally advanced unresectable metastatic soft tissue...
11518 Background: In our experience, combinatorial therapy with lower doses of doxorubicin, gemcitabine, and docetaxel has been effective a manageable toxicity profile in patients advanced soft tissue sarcomas. Hypothesis: The addition nivolumab will have synergistic effects improve treatment outcomes. Methods: Primary objective: To assess progression-free survival; Secondary objectives: (1) evaluate best overall response during period confirmed 6-week follow-up, (2) PFS rate at 6 9 months,...